疑似前列腺癌男性中基于MRI的活检决策的肿瘤学安全性
这项多中心纵向队列研究在德国柏林54家社区泌尿科诊所和2个影像中心纳入593例疑似前列腺癌男性,采用3-T多参数MRI指导活检决策并随访3年。阴性MRI者避免活检未显示临床显著前列腺癌风险升高,支持在具备程序性安全网时避免阴性MRI后立即活检的肿瘤学安全性。
要点
- 593例中286例(48%)MRI阴性,261例(44%)初始避免活检,3年内242例(41%)避免活检。
- 立即活检后161例(27%)检出临床显著前列腺癌,3年后增至172例(29%)。
- 阴性MRI者中7例立即活检诊断前列腺癌(含4例临床显著),279例进入监测,3年监测完成233例(84%)中7例诊断临床显著前列腺癌。
核心结论
- 在该队列研究中,多参数MRI阴性并避免活检的男性未显示临床显著前列腺癌风险升高。
- 研究证实,在具备程序性安全网时,阴性MRI后避免立即前列腺活检的活检前MRI策略具有肿瘤学安全性。
研究设计与样本
- 多中心纵向队列试验,在德国柏林54家社区泌尿科诊所和2家转诊学术机构放射影像中心开展。
- 纳入18至75岁临床疑似前列腺癌男性,于2016年9月至2017年12月入组,随访3年,最终分析报告于2023年12月23日。
- 参与者接受3-T多参数MRI;疑似前列腺癌者推荐靶向前列腺活检(诊断期);MRI阴性或MRI阳性但活检良性者系统监测3年(监测期),建议每6个月临床访视。
主要发现
- 共593例男性(中位[IQR]年龄64[58-70]岁)接受多参数MRI,286例(48%)MRI阴性,261例(44%)初始避免活检,242例(41%)3年内避免活检。
- 立即活检后161例(27%)检出临床显著前列腺癌,3年后增至172例(29%)。
- MRI阴性者中7例经立即活检诊断前列腺癌(含4例临床显著),279例进入监测;3年监测完成233例(84%),其中7例诊断临床显著前列腺癌。
- MRI阳性者307例中,58例(19%)立即活检后无前列腺癌,其中41例(71%)完成监测,4例(7%)诊断临床显著前列腺癌。
关键数值与推荐
- 临床显著前列腺癌定义为国际泌尿病理学会分级组≥2。
- MRI阴性者中7例立即活检诊断前列腺癌(含4例临床显著),279例进入监测。
- MRI阳性者307例中58例(19%)立即活检后无前列腺癌,其中41例(71%)完成监测,4例(7%)诊断临床显著前列腺癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The magnetic resonance imaging (MRI) pathway for diagnosing clinically significant prostate cancer (csPCa; defined as International Society of Urological Pathology grade group ≥2) uses multiparametric MRI (mpMRI) for prostate biopsy (PB) decision-making. However, the intermediate impact on patient outcomes in men with negative MRI results avoiding PB and men with positive MRI results without PCa remains unknown. OBJECTIVE: To assess the feasibility and safety of a community-based MRI diagnostic strategy in men with suspected PCa using 3-year active monitoring. DESIGN, SETTING, AND PARTICIPANTS: This multisite, longitudinal cohort trial took place across 54 community-based urology practices and 2 radiology imaging centers at a referral academic institution in Berlin, Germany. Eligible participants aged 18 to 75 years with clinically suspected PCa were enrolled between September 2016 and December 2017 and monitored for 3 years. Final analysis was reported on December 23, 2023. EXPOSURES: Participants underwent 3-T mpMRI. Men with findings suspected to be PCa were recommended for targeted PB (diagnostic phase). Men with negative mpMRI results or positive mpMRI results with benign findings at PB were systematically monitored for 3 years (monitoring phase). Clinical visits were recommended every 6 months. MAIN OUTCOMES AND MEASURES: The total proportion of men avoiding PB and those with csPCa. RESULTS: A total of 593 men (median [IQR] age, 64 [58-70] years) underwent mpMRI, with 286 (48%) having negative MRI results, 261 (44%) avoiding PB initially, and 242 (41%) avoiding PB over 3 years. csPCa was detected in 161 (27%) men after immediate PB, increasing to 172 (29%) men after 3 years. Seven men with negative MRI results were diagnosed with PCa by immediate PB (including 4 cases of csPCa), while 279 entered monitoring. Three-year monitoring was completed by 233 (84%) men, with 7 diagnoses of csPCa. Of 307 men with positive MRI results, 58 (19%) showed no PCa after immediate PB, of which 41 (71%) completed monitoring and 4 (7%) were diagnosed with csPCa. CONCLUSIONS AND RELEVANCE: In this cohort study, men with negative mpMRI results avoiding biopsy were not at elevated risk of csPCa. The study confirms the oncological safety of the prebiopsy MRI strategy of avoiding an immediate PB after negative MRI results when a programmatic safety net is in place.
引用
- Hamm CA, Asbach P, Pöhlmann A, et al. Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer. JAMA Oncol. 2025. PMID: 39666360. doi:10.1001/jamaoncol.2024.5497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。